ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RDY vs BMRN // EV/EBITDA & P/E VALUATION

Dr. Reddy's Laboratories Ltd (NYSE) VS. BioMarin Pharmaceutical Inc. (NASDAQ) • 15-METRIC TALLY: RDY 6 — BMRN 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RDY VS. BMRN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RDY BMRN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 77.70% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% 6.00% +3.90 RDY /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 21.0x 21.0x 0.00 TIE /valuation <GO>
Free Cash Flow Yield 2.21% 6.51% -4.30 BMRN /fcf-yield <GO>
Operating Margin 13.90% 12.70% +1.20 RDY /operating-margins <GO>
Net Profit Margin 10.90% 10.80% +0.10 RDY /net-margins <GO>
Revenue Growth (YoY) 6.60% 12.90% -6.30 BMRN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 5.57 -1.83 BMRN /balance-sheet <GO>
Piotroski F-Score Quality 8/9 8/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 76.2 54.4 +21.80 RDY /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.05 0.95 +0.10 RDY /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 26.8x +3.70 BMRN /forward-pe <GO>
Enterprise Scale & Market Cap $11.83B $11.33B $501.1M RDY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RDY REV BMRN REV RDY GROSS % BMRN GROSS % RDY FCF BMRN FCF
FY 2025 — $3.22B — 77.7% — $725.0M
FY 2024 — $2.85B — 79.7% — $487.4M
FY 2023 — $2.42B — — — $50.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RDY // BETA 1.05
BMRN // BETA 0.95